This website is intended for international healthcare professionals with an interest in the treatment of Nocturia. By clicking the link below you are declaring and confirming that you are a healthcare professional. Please answer a few short questions about this resource centre.

You are here

EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction

European Urology, Volume 67, Issue 6, June 2015, Pages 1099-1109



Lower urinary tract symptoms (LUTS) represent one of the most common clinical complaints in adult men and have multifactorial aetiology.


To develop European Association of Urology (EAU) guidelines on the assessment of men with non-neurogenic LUTS.

Evidence acquisition

A structured literature search on the assessment of non-neurogenic male LUTS was conducted. Articles with the highest available level of evidence were selected. The Delphi technique consensus approach was used to develop the recommendations.

Evidence synthesis

As a routine part of the initial assessment of male LUTS, a medical history must be taken, a validated symptom score questionnaire with quality-of-life question(s) should be completed, a physical examination including digital rectal examination should be performed, urinalysis must be ordered, post-void residual urine (PVR) should be measured, and uroflowmetry may be performed. Micturition frequency-volume charts or bladder diaries should be used to assess male LUTS with a prominent storage component or nocturia. Prostate-specific antigen (PSA) should be measured only if a diagnosis of prostate cancer will change the management or if PSA can assist in decision-making for patients at risk of symptom progression and complications. Renal function must be assessed if renal impairment is suspected from the history and clinical examination, if the patient has hydronephrosis, or when considering surgical treatment for male LUTS. Uroflowmetry should be performed before any treatment. Imaging of the upper urinary tract in men with LUTS should be performed in patients with large PVR, haematuria, or a history of urolithiasis. Imaging of the prostate should be performed if this assists in choosing the appropriate drug and when considering surgical treatment. Urethrocystoscopy should only be performed in men with LUTS to exclude suspected bladder or urethral pathology and/or before minimally invasive/surgical therapies if the findings may change treatment. Pressure-flow studies should be performed only in individual patients for specific indications before surgery or when evaluation of the pathophysiology underlying LUTS is warranted.


These guidelines provide evidence-based practical guidance for assessment of non-neurogenic male LUTS. An extended version is available online ( www.uroweb.org/guidelines ).

Patient summary

This article presents a short version of European Association of Urology guidelines for non-neurogenic male lower urinary tract symptoms (LUTS). The recommended tests should be able to distinguish between uncomplicated male LUTS and possible differential diagnoses and to evaluate baseline parameters for treatment. The guidelines also define the clinical profile of patients to provide the best evidence-based care. An algorithm was developed to guide physicians in using appropriate diagnostic tests.

Take Home Message

Non-neurogenic male lower urinary tract symptoms (LUTS) have multifactorial aetiology. Assessment should enable urologists to make a differential diagnosis between possible causes and define the clinical profile of men with non-neurogenic LUTS. These guidelines are based on the best available evidence and answer the clinical question as to which tests are recommended and when they should be performed in assessing non-neurogenic LUTS in men aged ≥40 yr.

Keywords: Clinical practice guidelines, Diagnosis, Lower urinary tract symptoms, Bladder outlet obstruction, Benign prostatic hyperplasia, Detrusor overactivity, Overactive bladder, Nocturia, Nocturnal polyuria.

1. Introduction

Lower urinary tract symptoms (LUTS) represent one of the most common clinical complaints in adult men [1] . The prevalence of LUTS increases with age, and estimates vary widely depending on definitions and cohorts studied[1] and [2]. LUTS have a major impact on health-related quality of life (QoL) [2] and are associated with substantial personal and societal costs [3] .

LUTS can be divided into storage, voiding, and post-micturition symptoms, and have traditionally been related to bladder outlet obstruction (BOO) as a result of benign prostatic obstruction (BPO), which is often caused by benign prostatic enlargement (BPE) resulting from the histologic condition benign prostatic hyperplasia (BPH) [4] . Several recent studies have shown, however, that LUTS are not necessarily related to pathologies of the prostate. For instance, various types of bladder dysfunction may also be involved in the pathogenesis of LUTS, which is sometimes urodynamically manifest as detrusor overactivity (during the storage phase) or underactivity (during the voiding phase). In addition, many other conditions, both urological and nonurological, may also contribute to LUTS ( Fig. 1 ).


Fig. 1 Causes of male lower urinary tract symptoms (LUTS). OAB = overactive bladder.

1.1. Scope and purpose of the guidelines

Owing to the high prevalence of LUTS and the underlying multifactorial pathophysiology, accurate assessment of male LUTS is crucial to establish a differential diagnosis among possible causes and to define the clinical profile of men with LUTS to provide the best evidence-based care (overall objectives). The assessment should be able to identify patients for whom watchful waiting (WW) or medical or surgical treatment can be recommended, as well as men at risk of disease progression, and to assess patients’ values and preferences. The guidelines aim to answer the clinical question as to which tests are recommended in the assessment of non-neurogenic LUTS in men aged ≥40 yr and when these tests should be performed.

2. Evidence acquisition

The recommendations in these guidelines are based on a structured literature search for articles published in English according to the PubMed/Medline, Web of Science, and Cochrane databases between 1966 and October 1, 2013, including the search terms “lower urinary tract symptoms”, “benign prostatic hyperplasia”, “detrusor overactivity”, “overactive bladder”, “nocturia”, and “nocturnal polyuria” in combination with the prespecified diagnostic tests and the search limits “humans”, “adult men”, “review”, “randomised clinical trials”, “clinical trials”, and “meta-analysis”. Each extracted article was separately analysed, classified, and labelled with a level of evidence (LE) according to a classification system modified from the Oxford Centre for Evidence-based Medicine, ranging from systematic reviews of randomised trials (LE 1a, highest evidence level) to expert opinion (LE 4, lowest evidence level) (modified from [5] ).

The working panel used the Delphi technique consensus approach, which is based on the rationale that decisions captured systematically from a structured group of individuals (the working panel) are more valid than those from unstructured groups. When published information is scarce, experts can make inferences using other data from comparable contexts. Using bespoke software ( www.acord.it ), propositions were put to experts, who voted for their preference. The results from the group were then sent back anonymously to all participants, who were able to review their responses in the context of group-wide results. This practice conferred anonymity and allowed opinions to be expressed free from peer-group pressure. The web-based system offered participants the option to comment and justify their decisions anonymously. After consideration of the view of the group and a review of the comments, a second round of anonymous voting took place. Experts were encouraged to revise their earlier answers in light of the replies of other working panel members. Three iterations of the process were used, during which the range of the answers decreased and the group converged towards a consensus answer. The working panel predetermined the consensus level at 77% (7 out of 9) using the Delphi process, such that consensus on and recommendation for any test required support from at least 77% of the panel members. The panel has classified diagnostic tests into three categories: must, should, and may, which represents the highest, intermediate, and lowest levels of obligation, respectively.

Each recommendation is based on the strongest clinically relevant data as far as possible. However, it should be noted that when recommendations are graded, there is no automatic relationship between LE and grade of recommendation (GR). The availability of randomised controlled trials (RCTs) may not necessarily translate into a grade A recommendation if there are methodological limitations, disparity in published results, uncertainty about the balance between desirable and undesirable effects, uncertainty or variability in patients’ values and preferences, or uncertainty about whether the intervention represents wise use of resources. Alternatively, an absence of high-level evidence does not necessarily preclude a grade A recommendation; if there is considerable clinical experience and consensus to support a high-level recommendation, a grade A recommendation can be made. Such decisions are clearly indicated in Table 1 with an asterisk to denote “upgraded based on panel consensus”.

Table 1 Level of evidence and grade of recommendation for the assessment of non-neurogenic male lower urinary tract symptoms

Assessment tool LE GR
A medical history must always be taken from men with LUTS 4 A *
A validated symptom score questionnaire with QoL question(s) should be used for routine assessment of male LUTS in all patients and should be applied for re-evaluation of LUTS during treatment 3 B
Micturition FVCs or bladder diaries should be used to assess male LUTS with a prominent storage component or nocturia 3 B
FVCs should have a duration of at least 3 d 2b B
Physical examination including DRE should be a routine part of the assessment of male LUTS 3 B
Urinalysis (by dipstick or urinary sediment) must be used in the assessment of male LUTS 3 A *
PSA should be measured only if a diagnosis of prostate cancer will change the management or if PSA can assist in decision-making for patients at risk of progression of BPE 1b A
Renal function must be assessed if renal impairment is suspected based on history and clinical examination, if hydronephrosis is present, or when considering surgical treatment for male LUTS 3 A *
Measurement of PVR in male LUTS should be a routine part of the assessment 3 B
Uroflowmetry in the initial assessment of male LUTS may be performed and should be performed before any treatment 2b B
Imaging of the upper urinary tract (with US) in men with LUTS should be performed in patients with a large PVR, haematuria, or a history of urolithiasis 3 B
When considering medical treatment for male LUTS, imaging of the prostate (either by TRUS or transabdominal US) should be performed if it assists choice of the appropriate drug 3 B
When considering surgical treatment, imaging of the prostate (either by TRUS or abdominal US) should be performed 3 B
Urethrocystoscopy should be performed in men with LUTS to exclude suspected bladder or urethral pathology and/or before minimally invasive/surgical therapies if the findings may change treatment 3 B
PFS should be performed only in individual patients for specific indications before surgery or when evaluation of the underlying pathophysiology of LUTS is warranted 3 B
PFS should be performed in men who have had previous unsuccessful (invasive) treatment for LUTS 3 B
When considering surgery, PFS may be used for patients who cannot void >150 ml 3 C
When considering surgery in men with bothersome predominantly voiding LUTS, PFS may be performed in men with PVR >300 ml 3 C
When considering surgery in men with bothersome predominantly voiding LUTS, PFS may be performed in men aged >80 yr 3 C
When considering surgery in men with bothersome predominantly voiding LUTS, PFS should be performed in men aged <50 yr 3 B

* Upgraded based on panel consensus.

BPE = benign prostatic enlargement; FVC = frequency/volume chart; GR = grade of recommendation; LE = level of evidence; LUTS = lower urinary tract symptoms; PFS = pressure-flow study; PSA = prostate-specific antigen; PVR = post-void residual urine; QoL = quality of life; TRUS = transrectal US; US = ultrasound.

The working panel for the non-neurogenic male LUTS guidelines consists of experts with a urological and epidemiological background. Although the guidelines are written primarily for urologists, they can also be used by general practitioners, patients, and other stakeholders. The working panel intends to regularly update the content and recommendations according to the structure and classification systems given.

3. Diagnostic tests

Recommendations apply to men aged ≥40 yr who seek professional help for various non-neurogenic benign forms of LUTS. Men with LUTS not falling into this category (eg, concomitant neurological diseases, young age, prior lower urinary tract disease or surgery) usually require a more extensive work-up that is not covered by these guidelines but may include several of the tests mentioned in the following section. All recommendations for diagnostic tests, along with LE and GR, are summarised in Table 1 .

3.1. Medical history

Earlier guidelines on male LUTS and/or BPH emphasise the importance of assessing the patient's history[6], [7], [8], and [9]. The aim of obtaining a medical history is to identify potential causes of LUTS and relevant comorbidities, such as medical (eg, diabetes mellitus or insipidus, renal disease, heart failure, sleep apnoea) and neurological diseases (eg, Parkinson's disease, multiple sclerosis, cerebrovascular disease, spinal cord injury, or prolapsed intervertebral disc impinging on the spinal cord). It is further recommended to review current medication, and assess lifestyle habits, as well as emotional and psychological factors. The panel highlights the need to discuss the patient's perspectives regarding LUTS and possible treatment options. The patient should be reassured that the presence of LUTS does not indicate a higher prevalence of prostate cancer (PCa) compared with asymptomatic men[10] and [11].

As part of the urological/surgical history, a self-completed validated symptom questionnaire (Section 3.2 ) should be delivered to objectively identify and quantify LUTS. The same symptom questionnaire should subsequently be discussed with the patient during follow-up to assess therapeutic efficacy. Potential erectile and other forms of sexual dysfunction should be investigated (preferably with validated symptom questionnaires).

3.2. Symptom score questionnaires

During the past two decades, symptom scores have become a standard tool in the assessment of male LUTS. Existing guidelines on male LUTS and/or BPH recommend the use of validated symptom score questionnaires[6], [7], [8], and [9]. Several questionnaires are available, all of which are sensitive to symptom changes and treatment monitoring[12], [13], [14], [15], [16], [17], and [18].

The International Prostate Symptom Score (IPSS) is an eight-item (seven symptom questions and one global QoL question) questionnaire, initially created as the American Urological Association Symptom Index [14] . The International Consultation on Incontinence Questionnaire ICIQ-MLUTS was created from the ICS male questionnaire (which resulted from an outcome of the ICS BPH study) and is another widely used and validated patient-completed questionnaire for evaluating male LUTS [15] . A third questionnaire is the Danish Prostate Symptom Score (DAN-PSS) [13] , which is mainly used in Denmark and Finland. The IPSS includes only one overall QoL question, whereas the DAN-PSS and ICIQ-MLUTS assess the bother of individual LUTS.

Symptom scores are recommended for all patients during initial assessment as they are helpful in quantifying individual LUTS and identifying which type of symptoms (storage or voiding) are predominant, yet they are not disease-, age-, or gender-specific. Symptom scores can also be used to monitor response to therapy.

3.3. Frequency-volume charts and bladder diaries

Recording of the volume and time of each void by the patient is referred to as a frequency-volume chart (FVC). The record is known as a bladder diary if additional information is captured, such as fluid intake, use of pads, activities during recording, or symptom scores [4] . Parameters that can be derived from the FVC include: voiding frequency per 24 h; total voided volume per 24 h, including the fraction of urine produced during the night, known as the nocturnal polyuria index; and the volume of individual voids (mean and range).

FVCs are beneficial when assessing patients with bothersome storage LUTS, particularly nocturia, as they can underpin categorisation of the underlying mechanism(s)[19], [20], and [21]. FVCs are typically more accurate than patient recall[22] and [23], particularly for nocturia. However, FVC use may lead to a bladder training effect, and nights during FVC recording may be atypical since substantial variations in the frequency of nocturnal voids have been observed [24] . Hence, there is no agreement on standardising the approach to deriving the above information in LUTS evaluation [25] .

The observation duration should be long enough to avoid sampling errors, but short enough to avoid noncompliance [25] . Several studies have compared shorter (3–5 d) with longer (7 d) diary durations[26], [27], [28], [29], [30], and [31]. A 2009 systematic review of the literature recommended the use of ≥3 d [32] . A recent phase 1 study on the development and validation of a urinary diary suggested that the FVC duration should be ≥4 d [33] .

3.4. Physical examination and digital rectal examination (DRE)

A physical examination should be performed on the suprapubic area to rule out bladder distention, on the external genitalia to identify conditions that may cause or contribute to LUTS (eg, urethral discharge, phimosis, meatal stenosis, penile cancer), and on the perineum/lower limbs to evaluate motor/sensory function. Therefore, a physical examination is especially useful for differential diagnosis of LUTS.

DRE is an important examination in men with LUTS and may help to determine the coexistence of PCa, despite its low diagnostic value, and abnormalities of anal sphincter tone. DRE overestimates prostate volume (PV) in smaller prostates and underestimates PV in larger prostates, but is a sufficient method to discriminate whether PV is greater or less than 50 ml [34] . The capacity of DRE to estimate PV is helpful for choosing treatment options, as these depend on PV (eg, 5α-reductase inhibitors [5-ARIs], transurethral incision of the prostate, transurethral resection of the prostate, and others; see EAU Guidelines on the treatment of non-neurogenic male LUTS [35] ).

3.5. Urinalysis

Urinalysis (dipstick or sediment) is an inexpensive test that does not require sophisticated technical equipment, and it must be incorporated in the primary evaluation of any patient presenting with LUTS to determine conditions such as urinary tract infection and diabetes mellitus on the basis of abnormal findings (haematuria, proteinuria, pyuria, glucosuria, ketonuria, positive nitrite test). Therefore, urinalysis is helpful for the differential diagnosis of LUTS. Once abnormal findings have been diagnosed, further evaluation is recommended according to the standards provided in other EAU guidelines, such as those on non–muscle-invasive bladder cancer, muscle-invasive and metastatic bladder cancer, upper urinary tract urothelial cell carcinoma, primary urethral carcinoma, and urological infections[36], [37], [38], and [39].

Urinalysis is traditionally recommended in most guidelines for the primary management of patients with LUTS[40] and [41]. Even in the absence of controlled studies, there is general expert consensus that the benefits clearly outweigh the costs, although the use of urinalysis should always be associated with prognostic significance [42] . Nevertheless, despite official guidelines and the widespread use of urinalysis among urologists [43] , the value of urinary dipstick/microscopy for diagnosing urinary tract infection in patients with painless LUTS has recently been questioned [44] .

3.6. Prostate-specific antigen (PSA)

3.6.1. PSA and PV prediction

Several reports have demonstrated the reliability of serum PSA for predicting PV[45], [46], and [47]. However, determination of exact PV for an individual from PSA does not seem to be possible because of the relatively large standard deviation for the estimation curve [48] .

3.6.2. PSA and PCa probability

The role of serum PSA in the diagnosis of PCa is described in the EAU guidelines on prostate cancer [49] . The benefits and harms of using serum PSA testing to diagnose PCa in men with LUTS should be discussed with the patient, including the possibilities of false-positive and false-negative results, complications of subsequent transrectal ultrasound (TRUS)-guided biopsy, false-negative biopsies, and overdiagnosis and overtreatment of PCa [49] .

Serum PSA appears to be a stronger predictor of prostate growth than PV [50] . In addition, the PLESS study showed that PSA also predicted changes in LUTS, QoL/bother, and the maximum urinary flow rate (Qmax) [51] . In a longitudinal study of men managed conservatively, serum PSA was a highly significant predictor of clinical progression [52] . More importantly, in the placebo arms of large double-blind controlled studies, baseline serum PSA consistently predicted the risk of acute urinary retention (AUR) and BPE-related surgery[53] and [54]. Patients with BPO appear to have higher serum PSA and greater PV compared to men without BPO [55] . The positive predictive value (PPV) of PSA for detection of BPO was recently shown to be 68% [56] .

3.7. Renal function measurement

Renal function may be assessed by measurement of serum creatinine or calculation or determination of the estimated glomerular filtration rate (eGFR). Hydronephrosis, renal insufficiency, and urinary retention appear with greater prevalence in patients with symptoms or signs of BPO [57] . Even though BPO may be partly responsible for these complications, there is no conclusive evidence that BPO is the primary cause [57] . One study evaluated 246 men presenting with LUTS and found that 11% had renal insufficiency [58] . The same study also noted that it was rather rare to find patients with high creatinine levels due to BPO alone [58] . Comiter et al [59] reported that voiding dysfunction of a non-neurogenic aetiology did not appear to be a risk factor for elevated creatinine levels. In addition, in the MTOPS study, fewer than 1% of men with LUTS presented with renal insufficiency during the observational period of at least 4 yr [54] . In 2741 consecutive patients who presented with LUTS, a decrease inQmaxand a history of hypertension and/or diabetes were significantly associated with chronic kidney disease [60] . A recent study demonstrated thatQmaxcorrelated significantly with GFR in middle-aged men with moderate to severe LUTS[61] and [62]. In addition, patients with renal insufficiency have a higher risk of developing postoperative complications compared to those with normal renal function [63] .

3.8. Post-void residual urine

Post-void residual urine (PVR) can be measured by transabdominal ultrasonography, a bladder scan, or catheterisation. The interval between voiding and PVR measurement should be short [64] . Ultrasound (US) bladder volume measurement is generally the preferred approach for measuring PVR [64] , which is not necessarily associated with BOO, since high PVR can be a consequence of BOO and/or poor detrusor function (underactivity)[65] and [66].

It has been shown that for volumes >50 ml, the diagnostic accuracy of PVR measurement has PPV of 63% and a negative predictive value (NPV) of 52% in determining BOO [62] . A large PVR is not a contraindication for watchful waiting or medical therapy, although PVR indicates bladder dysfunction and predict a poor response to treatment, especially to WW. In both the MTOPS and ALTESS studies, high baseline PVR was associated with an increased risk of symptom deterioration[53] and [54]. In addition, monitoring of PVR changes over time could predict AUR occurrence; patients who subsequently developed AUR showed a steady increase in PVR [53] . This is of particular importance for the treatment of patients using antimuscarinic medication. By contrast, baseline PVR has little prognostic value for the risk of BPE-related invasive therapy in patients on α1-blocker therapy or WW [67] . However, owing to large test-retest variability and a lack of outcome studies, it is currently impossible to establish a PVR threshold for treatment decisions.

3.9. Uroflowmetry

Urinary flow rate assessment is a basic noninvasive urodynamic test that is widely used to evaluate the joint functioning of the lower urinary tract components (bladder and outlet). Key parameters areQmax, voided volume, and flow pattern. Uroflowmetry parameters should ideally be evaluated when the voided volume is >150 ml.Qmaxcan be subject to within-subject variation on the same or different days[68] and [69]; therefore, it is advisable to repeat uroflowmetry measurements when the voided volume is <150 ml orQmaxor the flow pattern is abnormal.

The diagnostic accuracy of uroflowmetry for detecting BOO varies considerably and is substantially influenced by diagnostic threshold values. AQmaxthreshold of 10 ml/s had specificity of 70%, PPV of 70%, and sensitivity of 47% for BOO. For aQmaxthreshold of 15 ml/s, specificity was 38%, PPV was 67%, and sensitivity was 82% [70] ; thus, uroflowmetry alone is unsuitable for detection and quantification of BOO. LowQmaxcan arise as a consequence of BOO [71] , detrusor underactivity, or an underfilled bladder [72] . Thus, uroflowmetry is limited as a diagnostic test as a consequence of the inability to discriminate underlying mechanisms in men with lowQmax.

Specificity can be improved by repeated flow-rate testing in individual patients. Uroflowmetry can be used to monitor treatment outcomes [73] and correlate symptoms with objective findings.

3.10. Imaging

3.10.1. Upper urinary tract

Routine imaging of the upper urinary tract in men with LUTS is not recommended as these patients are not generally at higher risk of upper tract malignancy or other abnormalities (including hydronephrosis, measurable degrees of renal insufficiency, renal cysts) compared to the general population (see above)[74], [75], [76], and [77].

Several arguments support the use of renal US in preference to intravenous urography (IVU). US allows better characterisation of renal masses, the possibility of investigating the liver and retroperitoneum at the same time, and evaluation of the bladder, PVR and prostate compared to IVU, at lower cost and without radiation exposure and side effects [75] .

3.10.2. Prostate

Imaging of the prostate can be performed using several imaging techniques including transabdominal US, TRUS, computed tomography (CT), and magnetic resonance (MR) imaging. In daily practice, however, imaging of the prostate by TRUS or transabdominal US is mainly used [75] .

PV measurement is important before treatment with 5-ARIs and for selection of an appropriate interventional treatment [35] . Recent data suggest that PV may predict which patients with LUTS will develop symptom progression and complications [54] . A large body of evidence documents the accuracy of TRUS in calculating PV. TRUS is superior to suprapubic (transabdominal) PV measurement because all three distances for the prostate can be measured more accurately via the transrectal approach[78] and [79]. The presence of a middle lobe protruding into the bladder may guide the treatment choice in patients scheduled for a minimally invasive approach.

US measurement of intravesical prostatic protrusion (IPP) has also been introduced. The concept is that a prostate median lobe protruding into the bladder can cause a valve ball type of BPO with incomplete opening and disruption of the funnelling effect of the bladder neck [80] . IPP correlated well with BPO, with PPV of 94% and NPV of 79% [80] , and also seems to predict successful outcome of trial without catheter after AUR[81] and [82]. Therefore, IPP may be a feasible option for diagnosing BPO in men with LUTS, but its role as a noninvasive alternative to pressure-flow studies (PFS) in the assessment of male LUTS is under evaluation, and currently no specific recommendations can be made.

3.10.3. Bladder/detrusor wall thickness and US-estimated bladder weight (UEBW)

For bladder wall thickness (BWT) assessment, the entire diameter of the bladder wall is measured, which represents the distance between the hyperechogenic mucosa and the hyperechogenic adventitia. For detrusor wall thickness (DWT) assessment, only the hypoechogenic detrusor sandwiched between the hyperechogenic mucosa and adventitia is measured [83] . It has been shown that BWT and DWT measurements have higher diagnostic accuracy in detecting BOO thanQmaxin free uroflowmetry or measurements of PVR, PV, or symptom severity [62] .

Disadvantages of the method include the lack of standardisation in terms of threshold values and bladder filling so far, with varying results for different bladder filling levels, and a lack of evidence of whether BWT or DWT is more clinically relevant [84] . The concept of bladder weight (BW) as a measure of bladder wall hypertrophy has also been introduced [85] . Comparison of UEBW and PFS revealed that UEBW could identify BOO with a diagnostic accuracy of 86.2% using a cutoff value of 35 g [86] . Measurement of BWT or DWT and UEBW may be a feasible option for diagnosing BOO in men with LUTS. The role of BWT, DWT, and UEBW as a noninvasive alternative to PFS in the assessment of male LUTS or BOO is under evaluation, and currently no specific recommendations can be made.

3.11. Urethrocystoscopy

Patients with a history of microscopic or gross haematuria, urethral stricture (or relevant risk factors, such as history of urethritis, urethral injury, urethral instrumentation, or previous urethral surgery), or bladder cancer who present with LUTS should undergo urethrocystoscopy during diagnostic evaluation.

Several studies have addressed whether urethrocystoscopy findings correlate with functional data[87], [88], and [89]. In the largest study, urethroscopic findings were correlated to urodynamic studies in 492 elderly men with LUTS [89] . Correlation between cystoscopic appearance (grade of bladder trabeculation and grade of urethral occlusion) and urodynamic indices, detrusor overactivity, and low compliance was observed. It should be noted, however, that BOO was present in approximately 15% of patients with normal cystoscopic findings, while approximately 8% of patients had no BOO even in the presence of severe trabeculation [89] .

Evaluation of a prostatic middle lobe in urethrocystocopic findings is necessary to determine the indication for certain interventional treatments, such as transurethral needle ablation and transurethral microwave therapy.

3.12. Urodynamics (computer urodynamic investigation)

In male LUTS, the most widespread urodynamic techniques used are filling cystometry (to assess the bladder storage phase) and PFS (to assess the voiding phase). The major aims of urodynamics are to explore the functional mechanisms of LUTS and identify potential risk factors for adverse outcomes (for informed/shared decision-making). Most parameters and diseases or conditions (eg, detrusor overactivity, low compliance, BOO/BPO, detrusor underactivity) are identified by urodynamic investigation.

3.12.1. Diagnosing BOO

PFS are the basis for identifying BOO and are the primary objective in ascertaining its presence. BOO involves increased detrusor pressure and decreased urinary flow during voiding. BOO/BPO has to be differentiated from detrusor underactivity, which is defined as decreased detrusor pressure during voiding in combination with a decreased urinary flow rate. During the storage phase, urodynamic testing of overactive bladder (OAB) patients may identify detrusor overactivity (DO), which is a urodynamic observation characterised by involuntary detrusor contractions during the filling phase, which may be spontaneous or provoked. OAB is diagnosed from the patient's symptoms, based on the presence of urgency, usually with increased daytime frequency, nocturia, and/or urgency incontinence [4] . Thus, the terms OAB and DO are not interchangeable. For instance, in one study, 21% of men with urinary urgency did not have DO [90] , and DO can be asymptomatic; several studies have described an association between BOO and DO[91] and [92].

In men with LUTS attributed to BPE, DO was present in 61% of patients (n = 1418) and independently associated with BOO grade and ageing. As BOO grade and patient age increased, DO prevalence increased, ranging from 50% in men without BOO to 83% in men with the most severe BOO [93] . Prevalence estimates of detrusor underactivity in men with LUTS vary between 11% and 40%[93] and [94]. Detrusor contractility does not appear to decline in long-term BOO, and surgical relief of BOO does not improve contractility[95] and [96]. No randomised studies were identified regarding the usefulness of cystometry in guiding clinical management for patients with LUTS. Furthermore, there are no published RCTs comparing standard investigation (uroflowmetry and PVR measurement) with PFS in men with LUTS and possible BPO.

Owing to the invasive nature of urodynamic testing because of catheter placement, computer urodynamic investigation is generally only offered once conservative treatment has failed. The panel attempted to suggest specific indications for PFS based on age, findings from other diagnostic tests, and previous treatments. These include situations in which the diagnosis of BPO is uncertain and the patient has a significant chance of additional problems such as detrusor overactivity or underactivity. The panel allocated different degrees of obligation for PFS in men >80 yr and men <50 yr, and this may reflect the lack of clear evidence ( Table 1 ). In addition, there was no consensus on whether PFS should or may be performed when considering surgery in men with bothersome predominantly voiding LUTS andQmax>10 ml/s, although the panel recognised that BOO is likely forQmax<10 ml/s and PFS are not necessarily needed. It should be underlined that patients with neurological disease, including those with previous radical pelvic surgery, should be assessed according to the EAU guidelines on neurogenic lower urinary tract dysfunction [97] .

3.12.2. Videourodynamics

Inclusion of intermittent synchronous x-ray imaging and filling of the bladder with contrast medium for cystometry and PFS is termed videourodynamics. The test provides additional anatomical information. During filling, imaging is usually undertaken in the postero-anterior axis and can show bladder configuration (bladder trabeculation and diverticula), vesico-ureteral reflux, or pelvic floor activity. During voiding, a 45° lateral projection is typically used and can show the exact location of BOO. Videourodynamics may be used when there is uncertainty regarding the mechanisms of voiding LUTS.

4. Conclusions

Tests are useful for diagnosis, monitoring, assessment of the prognosis for disease progression, treatment planning, prediction of treatment outcome, and ascertainment of patient values and preferences. Standardisation of LUTS assessment in men represents a significant challenge because of the low LE of existing studies. The guidelines presented here are not an update of the BPH guidelines published in 2004. The multifactorial view of the aetiology of LUTS has been adopted and a broader approach to the assessment of men suffering from LUTS has been introduced. In addition, for the first time in the male LUTS guidelines, the panel used the Delphi consensus method to strengthen the value of its recommendations. A practical algorithm based on the recommendations has been developed ( Fig. 2 ). It should also be noted that the low LE for the majority of diagnostic tests emphasises the need for high-LE studies to determine the value of each diagnostic tool.


Fig. 2 Algorithm for assessment of lower urinary tract symptoms (LUTS) in men aged ≥40 yr. DRE = digital rectal examination; PCa = prostate cancer; PSA = prostate-specific antigen; PVR = post-void residual urine; US = ultrasound.

Author contributions:Stavros Gravas had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design:Gravas, Gratzke, Bachmann, Descazeaud, Drake, Madersbacher, Mamoulakis, Oelke, Tikkinen.

Acquisition of data:Gravas, Gratzke, Bachmann, Descazeaud, Drake, Madersbacher, Mamoulakis, Oelke, Tikkinen.

Analysis and interpretation of data:Gravas, Gratzke, Bachmann, Descazeaud, Drake, Madersbacher, Mamoulakis, Oelke, Tikkinen.

Drafting of the manuscript:Gratzke, Gravas.

Critical revision of the manuscript for important intellectual content:Gravas, Gratzke, Bachmann, Descazeaud, Drake, Madersbacher, Mamoulakis, Oelke, Tikkinen.

Statistical analysis:Gravas.

Obtaining funding:None.

Administrative, technical, or material support:Gravas, Gratzke.



Financial disclosures:Stavros Gravas certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: Stavros Gravas has received grants or research support from Pierre Fabre Medicament and GSK, travel grants from Angelini Pharma Hellas, Astellas, GSK, and Pierre Fabre Medicament, and speaker honoraria from Angelini Pharma Hellas, Pierre Fabre Medicament, Lilly, and GSK, and is a consultant for Pierre Fabre Medicament and GSK. Christian Gratzke has received grants or research support from MSD, Bayer Healthcare, AMS, and Recordati, fellowship and travel grants from DFG and EUSP, and speaker honoraria from Rottapharm-Madaus, Astellas Pharma, GSK, AMS, and Steba, and is a consultant for Rottapharm-Madaus, Astellas Pharma, Lilly, Recordati, Bayer, and Dendreon. Alexander Bachmann has received grants or research support from AstraZeneca and Pfizer, and speaker honoraria from AMS, Ferring, and Bayer, has participated in trials by AstraZeneca, Pfizer, and AMS, and is a consultant for AMS, Orionpharma, Schering, Olympus, and Caris Life. Aurelien Descazeaud has received speaker honoraria from Takeda, GSK, Pierre Fabre, and Lilly, has participated in trials by Olympus, Lumenis, AMS, Allergan, Recordati, Takeda, and Pierre Fabre, and is a consultant for Sanofi, Pierre Fabre, Lilly, and Recordati. Marcus J. Drake has received grants or research support from Ferring and Astellas, fellowship or travel grants from Astellas, honoraria or consultation fees from Allergan, Astellas, and Apogepha, and speaker honoraria from Apogepha, Ferring, Pfizer, Astellas, and Allergan, has participated in trials by Allergan and Astellas, and is a consultant for J&J. Stephan Madersbacher has received speaker honoraria from Lilly, Takeda, Astellas, MSD, GSK, and Böhringer Ingelheim, and is a member of the advisory boards for Lilly, Astellas, Takeda, and GSK. Charalampos Mamoulakis has received grants or research support from Porge-Coloplast and Ariti, honoraria or consultation fees from Astellas, fellowship or travel grants from Karl Storz Endoscope, Porge-Coloplast, Cook Medical, Boston Scientific, and Astellas, and a speaker honorarium from GSK, and has participated in trials by Medivation, Karl Storz Endoscope, Eli Lilly, and Astellas. Matthias Oelke has received grants or research support from Pfizer, Astellas, and Ferring, fellowship or travel grants from Astellas, Apogepha, Recordati, Eli-Lilly, GSK, Pfizer, and Mundipharma, honoraria or consultation fees from Astellas, Allergan, and Teva, and speaker honoraria from Allergan, Pfizer, Bayer Healthcare, Eli-Lilly, GSK, Ferring, and Astellas, has participated in trials by Ferring, Apogepha, Pfizer, Astellas, Allergan, Eli-Lilly, and GT-Urological, is a consultant for Apogepha, Teva, Sophiris, GT-Urological, Recordati, Pfizer, Mundipharma, Eli-Lilly, Biocompatibles, GSK, and Astellas. Kari A.O. Tikkinen has nothing to disclose.

Funding/Support and role of the sponsor:None.


  • [1] S.A. Martin, M.T. Haren, V.R. Marshall, K. Lange, G.A. Wittert. Prevalence and factors associated with uncomplicated storage and voiding lower urinary tract symptoms in community-dwelling Australian men. World J Urol. 2011;29:179-184 Crossref
  • [2] V. Kupelian, J.T. Wei, M.P. O’Leary, et al. Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. Arch Intern Med. 2006;166:2381-2387 Crossref
  • [3] D.A. Taub, J.T. Wei. The economics of benign prostatic hyperplasia and lower urinary tract symptoms in the United States. Curr Urol Rep. 2006;7:272-281 Crossref
  • [4] P. Abrams, L. Cardozo, M. Fall, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21:167-178 Crossref
  • [5] Phillips B, Ball C, Sackett D, et al. Oxford Centre for Evidence-based Medicine—levels of evidence (March 2009). Centre for Evidence-Based Medicine Web site. http://www.cebm.net/index.aspx?o=1025 . Accessed February 2014.
  • [6] G. Novara, A. Galfano, M. Gardi, V. Ficarra, L. Boccon-Gibod, W. Artibani. Critical review of guidelines for BPH diagnosis and treatment strategy. Eur Urol Suppl. 2006;4:418-429 Crossref
  • [7] J. Irani, C.T. Brown, J. van der Meulen, M. Emberton. A review of guidelines on benign prostatic hyperplasia and lower urinary tract symptoms: are all guidelines the same?. BJU Int. 2003;92:937-942 Crossref
  • [8] K.T. McVary, C.G. Roehrborn, A.L. Avins, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185:1793-1803 Crossref
  • [9] J. Bosch, P. Abrams, N. Cotterill, et al. Etiology, patient assessment and predicting outcome from therapy. C. Chapple, P. Abrams (Eds.) Male lower urinary tract symptoms (International Consultation on Urological Diseases Male LUTS Guideline, Montreal, Canada, 2013) 37-133
  • [10] J.M. Young, D.J. Muscatello, J.E. Ward. Are men with lower urinary tract symptoms at increased risk of prostate cancer? A systematic review and critique of the available evidence. BJU Int. 2000;85:1037-1048 Crossref
  • [11] R.M. Martin, L. Vatten, D. Gunnell, P. Romundstad, T.I. Nilsen. Lower urinary tract symptoms and risk of prostate cancer: the HUNT 2 Cohort, Norway. Int J Cancer. 2008;123:1924-1928 Crossref
  • [12] A.B. Barqawi, K.F. Sullivan, E.D. Crawford, et al. Methods of developing UWIN, the modified American Urological Association symptom score. J Urol. 2011;186:940-944 Crossref
  • [13] J. Schou, A.L. Poulsen, J. Nordling. The value of a new symptom score (DAN-PSS) in diagnosing uro-dynamic infravesical obstruction in BPH. Scand J Urol Nephrol. 1993;27:489-492 Crossref
  • [14] M.J. Barry, F.J. Fowler Jr., M.P. O’Leary, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148:1549-1557
  • [15] J.L. Donovan, T.J. Peters, P. Abrams, S.T. Brookes, J.J. de aa Rosette, W. Schafer. Scoring the short form ICSmaleSF questionnaire. International Continence Society. J Urol. 2000;164:1948-1955
  • [16] Y. Homma, M. Yoshida, N. Seki, et al. Symptom assessment tool for overactive bladder syndrome—overactive bladder symptom score. Urology. 2006;68:318-323 Crossref
  • [17] Y. Homma, M. Yoshida, T. Yamanishi, M. Gotoh. Core Lower Urinary Tract Symptom score (CLSS) questionnaire: a reliable tool in the overall assessment of lower urinary tract symptoms. Int J Urol. 2008;15:816-820 Crossref
  • [18] R.S. Epstein, P.A. Deverka, C.G. Chute, et al. Validation of a new quality of life questionnaire for benign prostatic hyperplasia. J Clin Epidemiol. 1992;45:1431-1445 Crossref
  • [19] J.N. Cornu, P. Abrams, C.R. Chapple, et al. A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management—a systematic review and meta-analysis. Eur Urol. 2012;62:877-890 Crossref
  • [20] J.P. Weiss. Nocturia: “do the math”. J Urol. 2006;175:S16-S18 Crossref
  • [21] J.P. Weiss, J.L. Ruud Bosch, M. Drake, et al. Nocturia think tank: focus on nocturnal polyuria: ICI-RS 2011. Neurourol Urodyn. 2012;31:330-339 Crossref
  • [22] M.H. Blanker, A.M. Bohnen, F.P. Groeneveld, R.M. Bernsen, A. Prins, J.L. Ruud Bosch. Normal voiding patterns and determinants of increased diurnal and nocturnal voiding frequency in elderly men. J Urol. 2000;164:1201-1205
  • [23] E.P. van Haarst, J.L. Bosch, E.A. Heldeweg. The International Prostate Symptom Score overestimates nocturia assessed by frequency-volume charts. J Urol. 2012;188:211-215 Crossref
  • [24] C.P. Vaughan, T.M. Johnson II, P.S. Goode, D.T. Redden, K.L. Burgio, A.D. Markland. Military exposure and urinary incontinence among American men. J Urol. 2014;191:125-129 Crossref
  • [25] E. Bright, M.J. Drake, P. Abrams. Urinary diaries: evidence for the development and validation of diary content, format, and duration. Neurourol Urodyn. 2011;30:348-352 Crossref
  • [26] J.S. Brown, K.S. McNaughton, J.F. Wyman, et al. Measurement characteristics of a voiding diary for use by men and women with overactive bladder. Urology. 2003;61:802-809 Crossref
  • [27] D. Gordon, A. Groutz. Evaluation of female lower urinary tract symptoms: overview and update. Curr Opin Obstet Gynecol. 2001;13:521-527 Crossref
  • [28] Y. Homma, T. Ando, M. Yoshida, et al. Voiding and incontinence frequencies: variability of diary data and required diary length. Neurourol Urodyn. 2002;21:204-209 Crossref
  • [29] J.H. Ku, I.G. Jeong, D.J. Lim, S.S. Byun, J.S. Paick, S.J. Oh. Voiding diary for the evaluation of urinary incontinence and lower urinary tract symptoms: prospective assessment of patient compliance and burden. Neurourol Urodyn. 2004;23:331-335 Crossref
  • [30] J.L. Locher, P.S. Goode, D.L. Roth, R.L. Worrell, K.L. Burgio. Reliability assessment of the bladder diary for urinary incontinence in older women. J Gerontol A Biol Sci Med Sci. 2001;56:M32-M35 Crossref
  • [31] I. Nygaard, R. Holcomb. Reproducibility of the seven-day voiding diary in women with stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct. 2000;11:15-17 Crossref
  • [32] T.L. Yap, D.C. Cromwell, M. Emberton. A systematic review of the reliability of frequency-volume charts in urological research and its implications for the optimum chart duration. BJU Int. 2007;99:9-16 Crossref
  • [33] E. Bright, N. Cotterill, M. Drake, P. Abrams. Developing a validated urinary diary: phase 1. Neurourol Urodyn. 2012;31:625-633 Crossref
  • [34] J.L. Bosch, A.M. Bohnen, F.P. Groeneveld. Validity of digital rectal examination and serum prostate specific antigen in the estimation of prostate volume in community-based men aged 50 to 78 years: the Krimpen Study. Eur Urol. 2004;46:753-759 Crossref
  • [35] M. Oelke, A. Bachmann, A. Descazeaud, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013;64:118-140 Crossref
  • [36] J. Palou, D. Wood, B.H. Bochner, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: urothelial carcinoma of the prostate. Eur Urol. 2013;63:81-87 Crossref
  • [37] M. Roupret, M. Babjuk, E. Comperat, et al. European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol. 2013;63:1059-1071 Crossref
  • [38] M. Burger, W. Oosterlinck, B. Konety, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013;63:36-44 Crossref
  • [39] Grabe M, Bjerklund-Johansen TE, Botto H, et al. Guidelines on urological infections. European Association of Urology; 2013. http://www.uroweb.org
  • [40] C.G. Roehrborn, G. Bartsch, R. Kirby, et al. Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: a comparative, international overview. Urology. 2001;58:642-650 Crossref
  • [41] P. Abrams, C. Chapple, S. Khoury, C. Roehrborn, J. de la Rosette. Evaluation and treatment of lower urinary tract symptoms in older men. J Urol. 2013;189(1 Suppl):S93-S101 Crossref
  • [42] European Confederation of Laboratory Medicine. European urinalysis guidelines. Scand J Clin Lab Invest Suppl. 2000;231:1-86
  • [43] J.T. Wei, M.M. Miner, W.D. Steers, et al. Benign prostatic hyperplasia evaluation and management by urologists and primary care physicians: practice patterns from the observational BPH registry. J Urol. 2011;186:971-976 Crossref
  • [44] R. Khasriya, S. Khan, R. Lunawat, et al. The inadequacy of urinary dipstick and microscopy as surrogate markers of urinary tract infection in urological outpatients with lower urinary tract symptoms without acute frequency and dysuria. J Urol. 2010;183:1843-1847 Crossref
  • [45] T.A. Stamey, N. Yang, A.R. Hay, J.E. McNeal, F.S. Freiha, E. Redwine. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317:909-916 Crossref
  • [46] C.G. Roehrborn, P. Boyle, A.L. Gould, J. Waldstreicher. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology. 1999;53:581-589 Crossref
  • [47] A.M. Bohnen, F.P. Groeneveld, J.L. Bosch. Serum prostate-specific antigen as a predictor of prostate volume in the community: the Krimpen study. Eur Urol. 2007;51:1645-1652
  • [48] C.A. Mochtar, L.A. Kiemeney, M.M. van Riemsdijk, et al. Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia. Eur Urol. 2003;44:695-700 Crossref
  • [49] A. Heidenreich, P.J. Bastian, J. Bellmunt, et al. EAU Guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent—update 2013. Eur Urol. 2014;65:124-137 Crossref
  • [50] C.G. Roehrborn, J. McConnell, J. Bonilla, et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. J Urol. 2000;163:13-20
  • [51] C.G. Roehrborn, P. Boyle, D. Bergner, et al. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology. 1999;54:662-669 Crossref
  • [52] B. Djavan, Y.K. Fong, M. Harik, et al. Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years. Urology. 2004;64:1144-1148 Crossref
  • [53] C.G. Roehrborn. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. BJU Int. 2006;97:734-741 Crossref
  • [54] J.D. McConnell, C.G. Roehrborn, O.M. Bautista, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387-2398 Crossref
  • [55] M.Y. Kang, J.H. Ku, S.J. Oh. Non-invasive parameters predicting bladder outlet obstruction in Korean men with lower urinary tract symptoms. J Korean Med Sci. 2010;25:272-275 Crossref
  • [56] K.B. Lim, H. Ho, K.T. Foo, M.Y. Wong, S. Fook-Chong. Comparison of intravesical prostatic protrusion, prostate volume and serum prostatic-specific antigen in the evaluation of bladder outlet obstruction. Int J Urol. 2006;13:1509-1513 Crossref
  • [57] M. Oelke, R. Kirschner-Hermanns, N. Thiruchelvam, J. Heesakkers. Can we identify men who will have complications from benign prostatic obstruction (BPO)? ICI-RS 2011. Neurourol Urodyn. 2012;31:322-326 Crossref
  • [58] G.S. Gerber, E.R. Goldfischer, T.G. Karrison, G.T. Bales. Serum creatinine measurements in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology. 1997;49:697-702 Crossref
  • [59] C.V. Comiter, M.P. Sullivan, R.S. Schacterle, L.H. Cohen, S.V. Valla. Urodynamic risk factors for renal dysfunction in men with obstructive and nonobstructive voiding dysfunction. J Urol. 1997;158:181-185 Crossref
  • [60] S.K. Hong, S.T. Lee, S.J. Jeong, et al. Chronic kidney disease among men with lower urinary tract symptoms due to benign prostatic hyperplasia. BJU Int. 2010;105:1424-1428
  • [61] J.H. Lee, H. Kwon, Y.W. Park, I.C. Cho, S.K. Min. Relationship of estimated glomerular filtration rate with lower urinary tract symptoms/benign prostatic hyperplasia measures in middle-aged men with moderate to severe lower urinary tract symptoms. Urology. 2013;82:1381-1385 Crossref
  • [62] M. Oelke, K. Hofner, U. Jonas, J.J. de la Rosette, D.T. Ubbink, H. Wijkstra. Diagnostic accuracy of noninvasive tests to evaluate bladder outlet obstruction in men: detrusor wall thickness, uroflowmetry, postvoid residual urine, and prostate volume. Eur Urol. 2007;52:827-834
  • [63] W.K. Mebust, H.L. Holtgrewe, A.T. Cockett, P.C. Peters. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol. 1989;141:243-247
  • [64] Asimakopoulos AD, De Nunzio C, Kocjancic E, Tubaro A, Rosier PF, Finazzi-Agro E. Measurement of post-void residual urine. Neurourol Urodyn. In press. http://dx.doi.org/10.1002/nau.22671
  • [65] A.D. Rule, D.J. Jacobson, M.E. McGree, C.J. Girman, M.M. Lieber, S.J. Jacobsen. Longitudinal changes in post-void residual and voided volume among community dwelling men. J Urol. 2005;174:1317-1321
  • [66] M.P. Sullivan, S.V. Yalla. Detrusor contractility and compliance characteristics in adult male patients with obstructive and nonobstructive voiding dysfunction. J Urol. 1996;155:1995-2000
  • [67] C.A. Mochtar, L.A. Kiemeney, M.M. van Riemsdijk, M.P. Laguna, F.M. Debruyne, J.J. de la Rosette. Post-void residual urine volume is not a good predictor of the need for invasive therapy among patients with benign prostatic hyperplasia. J Urol. 2006;175:213-216 Crossref
  • [68] R. Kranse, R. van Mastrigt. Causes for variability in repeated pressure-flow measurements. Urology. 2003;61:930-934 Crossref
  • [69] J.B. Jorgensen, K.M. Jensen, P. Mogensen. Age-related variation in urinary flow variables and flow curve patterns in elderly males. Br J Urol. 1992;69:265-271 Crossref
  • [70] J.M. Reynard, Q. Yang, J.L. Donovan, et al. The ICS-BPH study: uroflowmetry, lower urinary tract symptoms and bladder outlet obstruction. Br J Urol. 1998;82:619-623 Crossref
  • [71] T. Idzenga, J.J. Pel, R. van Mastrigt. Accuracy of maximum flow rate for diagnosing bladder outlet obstruction can be estimated from the ICS nomogram. Neurourol Urodyn. 2008;27:97-98 Crossref
  • [72] M.B. Siroky, C.A. Olsson, R.J. Krane. The flow rate nomogram: I. Development. J Urol. 1979;122:665-668
  • [73] M.B. Siroky, C.A. Olsson, R.J. Krane. The flow rate nomogram: II. Clinical correlation. J Urol. 1980;123:208-210
  • [74] A. Thorpe, D. Neal. Benign prostatic hyperplasia. Lancet. 2003;361:1359-1367 Crossref
  • [75] G.D. Grossfeld, F.V. Coakley. Benign prostatic hyperplasia: clinical overview and value of diagnostic imaging. Radiol Clin North Am. 2000;38:31-47 Crossref
  • [76] A.G. Wilkinson, S.R. Wild. Is pre-operative imaging of the urinary tract worthwhile in the assessment of prostatism?. Br J Urol. 1992;70:53-57 Crossref
  • [77] W.F. Koch, K. Ezz el Din, M.J. de Wildt, F.M. Debruyne, J.J. de la Rosette. The outcome of renal ultrasound in the assessment of 556 consecutive patients with benign prostatic hyperplasia. J Urol. 1996;155:186-189
  • [78] A.C. Loch, A. Bannowsky, L. Baeurle, et al. Technical and anatomical essentials for transrectal ultrasound of the prostate. World J Urol. 2007;25:361-366 Crossref
  • [79] K.G. Stravodimos, A. Petrolekas, T. Kapetanakis, et al. TRUS versus transabdominal ultrasound as a predictor of enucleated adenoma weight in patients with BPH: a tool for standard preoperative work-up?. Int Urol Nephrol. 2009;41:767-771 Crossref
  • [80] S.J. Chia, C.T. Heng, S.P. Chan, K.T. Foo. Correlation of intravesical prostatic protrusion with bladder outlet obstruction. BJU Int. 2003;91:371-374 Crossref
  • [81] Y.H. Tan, K.T. Foo. Intravesical prostatic protrusion predicts the outcome of a trial without catheter following acute urine retention. J Urol. 2003;170:2339-2341 Crossref
  • [82] P. Mariappan, D.J. Brown, A.S. McNeill. Intravesical prostatic protrusion is better than prostate volume in predicting the outcome of trial without catheter in white men presenting with acute urinary retention: a prospective clinical study. J Urol. 2007;178:573-577 Crossref
  • [83] M. Arnolds, M. Oelke. Positioning invasive versus noninvasive urodynamics in the assessment of bladder outlet obstruction. Curr Opin Urol. 2009;19:55-62 Crossref
  • [84] M. Oelke. International Consultation on Incontinence-Research Society (ICI-RS) report on non-invasive urodynamics: the need of standardization of ultrasound bladder and detrusor wall thickness measurements to quantify bladder wall hypertrophy. Neurourol Urodyn. 2010;29:634-639 Crossref
  • [85] M. Kojima, E. Inui, A. Ochiai, Y. Naya, O. Ukimura, H. Watanabe. Ultrasonic estimation of bladder weight as a measure of bladder hypertrophy in men with infravesical obstruction: a preliminary report. Urology. 1996;47:942-947 Crossref
  • [86] M. Kojima, E. Inui, A. Ochiai, Y. Naya, O. Ukimura, H. Watanabe. Noninvasive quantitative estimation of infravesical obstruction using ultrasonic measurement of bladder weight. J Urol. 1997;157:476-479
  • [87] I. Shoukry, J.G. Susset, M.M. Elhilali, D. Dutartre. Role of uroflowmetry in the assessment of lower urinary tract obstruction in adult males. Br J Urol. 1975;47:559-566 Crossref
  • [88] R.M. Anikwe. Correlations between clinical findings and urinary flow rate in benign prostatic hypertrophy. Int Surg. 1976;61:392-394
  • [89] K.E. el Din, L.A. Kiemeney, M.J. de Wildt, P.F. Rosier, F.M. Debruyne, J.J. de la Rosette. The correlation between bladder outlet obstruction and lower urinary tract symptoms as measured by the international Prostate Symptom Score. J Urol. 1996;156:1020-1025
  • [90] H. Hashim, P. Abrams. Is the bladder a reliable witness for predicting detrusor overactivity?. J Urol. 2006;175:191-194 Crossref
  • [91] M.M. Oh, H. Choi, M.G. Park, et al. Is there a correlation between the presence of idiopathic detrusor overactivity and the degree of bladder outlet obstruction?. Urology. 2011;77:167-170 Crossref
  • [92] M. Oelke, J. Baard, H. Wijkstra, J.J. de la Rosette, U. Jonas, K. Hofner. Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. Eur Urol. 2008;54:419-426 Crossref
  • [93] A.W. Thomas, A. Cannon, E. Bartlett, J. Ellis-Jones, P. Abrams. The natural history of lower urinary tract dysfunction in men: the influence of detrusor underactivity on the outcome after transurethral resection of the prostate with a minimum 10-year urodynamic follow-up. BJU Int. 2004;93:745-750 Crossref
  • [94] S.J. Jeong, H.J. Kim, Y.J. Lee, et al. Prevalence and clinical features of detrusor underactivity among elderly with lower urinary tract symptoms: a comparison between men and women. Korean J Urol. 2012;53:342-348 Crossref
  • [95] A.W. Thomas, A. Cannon, E. Bartlett, J. Ellis-Jones, P. Abrams. The natural history of lower urinary tract dysfunction in men: minimum 10-year urodynamic followup of transurethral resection of prostate for bladder outlet obstruction. J Urol. 2005;174:1887-1891 Crossref
  • [96] S. Al-Hayek, A. Thomas, P. Abrams. Natural history of detrusor contractility—minimum ten-year urodynamic follow-up in men with bladder outlet obstruction and those with detrusor. Scand J Urol Nephrol Suppl. 2004;(215):101-108 Crossref
  • [97] M. Stohrer, B. Blok, D. Castro-Diaz, et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol. 2009;56:81-88 Crossref


a Department of Urology, Urologische Klinik und Poliklinik, Klinikum der Universität München-Grosshadern, Munich, Germany

b Department of Urology, University Hospital Basel, Basel, Switzerland

c Department of Urology, Dupuytren Hospital, University of Limoges, Limoges, France

d Bristol Urological Institute and School of Clinical Sciences, University of Bristol, Bristol, UK

e Department of Urology and Andrology, Kaiser-Franz-Josef Spital, Vienna, Austria

f Department of Urology, University General Hospital of Heraklion, University of Crete Medical School, Heraklion, Crete, Greece

g Department of Urology, Hannover Medical School, Hannover, Germany

h Departments of Urology and Public Health, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland

i Department of Urology, University of Thessaly, Larissa, Greece

lowast Corresponding author. Department of Urology, University of Thessaly, Feidiou 6–8, Larissa 41221, Greece. Tel. +30 69 44626086; Fax: +30 24 13501900.